#United States #San Diego #Azitra #BIO Convention #Precision Dermatology

Azitra, Inc. to Present at the 2026 BIO International Convention

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company based in Branford, Connecticut, is poised to make significant waves at the upcoming 2026 BIO International Convention scheduled for June 22-25, 2026, in San Diego, California. The company specializes in developing cutting-edge therapies aimed at precision dermatology, targeting unmet medical needs with innovative solutions.

Event Details and Presentation

The spotlight will be on Travis Whitfill, Ph.D., MPH, who is the co-founder and Chief Operating Officer of Azitra. He will be presenting on June 23, 2026, at 4:45 PM PT, in Theater 1 of the San Diego Convention Center. During his presentation, Dr. Whitfill will discuss the latest advancements in Azitra’s pipeline, particularly focusing on an innovative protein and peptide program designed for the cosmetic and cosmeceutical markets. This groundbreaking initiative leverages the company’s proprietary filaggrin technologies, which promise to enhance dermatological therapies significantly.

In addition to the presentation, Dr. Whitfill will host one-on-one meetings with registered investors and potential partners during the conference. These sessions will provide an exclusive opportunity for interested parties to learn more about Azitra's comprehensive business strategy, recent achievements, and future developments in clinical research and product innovation.

About Azitra

Founded to address the challenges faced in dermatological health, Azitra operates in a niche that remains largely unaddressed. The firm’s flagship program, ATR-12, is based on an engineered strain of S. epidermidis, specifically designed to treat Netherton syndrome—a rare and severe skin condition that currently has no FDA-approved therapeutic options. This debilitating condition can be fatal in infancy; hence, the company's mission is especially critical. ATR-12 is presently undergoing a Phase 1b clinical trial, aiming to assess its safety and efficacy in adult patients suffering from this disorder.

In addition, Azitra is advancing its ATR-04 program, which utilizes another engineered strain of S. epidermidis targeted at managing rash associated with EGFR inhibitors, a common side effect for many cancer patients. With approximately 150,000 individuals affected by this issue in the U.S., Azitra’s work has garnered Fast Track designation from the FDA, reinforcing its importance in improving patient outcomes.

Technological Innovation

What sets Azitra apart is its proprietary platform comprising engineered proteins and topical live biotherapeutic products derived from an extensive microbial library of around 1,500 bacterial strains. The integration of artificial intelligence and machine learning supports the identification and development of drug-like molecules from this microbial library, enhancing the efficiency and effectiveness of the drug development process.

Furthermore, Azitra is extending its innovative capabilities to the consumer and cosmeceutical markets through the development of novel filaggrin protein and peptide technologies. This thrust into the cosmetic space is part of a broader strategy to harness the company’s foundational microbial genetic engineering platform in diverse applications, bolstering its role as a leader in dermatological advancements.

Conclusion

As Azitra prepares for its presentation at the BIO International Convention, it reinforces its commitment to delivering innovative treatments in precision dermatology. This event not only serves as a platform for Azitra to showcase its significant strides in research and development but also highlights the company’s dedication to improving dermatological health through scientific innovation. Keep an eye on Azitra as it moves forward to reshape the landscape of dermatological therapies and potentially transform the lives of many patients experiencing challenging skin conditions.